about
A review of omalizumab for the management of severe asthmaGuideline of Chronic Urticaria BeyondEmerging therapies for severe asthmaSevere asthma: anti-IgE or anti-IL-5?Therapeutic interventions in severe asthmaRisk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization StatementTreating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewOff-target platelet activation in macaques unique to a therapeutic monoclonal antibody.Asthma that is unresponsive to usual careOmalizumab in the treatment of asthma.Omalizumab in children.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Omalizumab, an anti-immunoglobulin E antibody: state of the art.Update on optimal use of omalizumab in management of asthma.Helping patients attain and maintain asthma control: reviewing the role of the nurse practitioner.Optimal management of severe/refractory asthma.Pharmacotherapy of severe asthmaType 2 inflammation in asthma--present in most, absent in manyAnti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.Omalizumab: clinical use for the management of asthma.Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.Retrospective analysis of the efficacy of omalizumab in chronic refractory urticariaAntibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation.Managing asthma in primary care: putting new guideline recommendations into context.A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivoRoflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Omalizumab for pediatric asthma.Safety of omalizumab in asthma.Can anti-IgE therapy prevent airway remodeling in allergic asthma?Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Omalizumab: a review of its use in patients with severe persistent allergic asthma.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Biological Modulators in Eosinophilic Diseases.The discovery and development of omalizumab for the treatment of asthma.Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines.Omalizumab therapy for children and adolescents with severe allergic asthma.Ethnic differences in adverse drug reactions to asthma medications: a systematic review.
P2860
Q26741315-9B35277C-522D-42C8-9C69-5102E16CFD3DQ26743369-33F06197-4164-40C9-84C5-83C1A5ABDE32Q26861260-94FA5D1F-BB17-436E-A411-8AEAE01CA97AQ28071832-A303D30F-80BC-4284-ABF9-12E60516D949Q28079238-B6AE7C86-CE22-45AF-9845-6022F0C2E069Q30371972-F410515A-6E09-440C-AE9E-3E05A1AA1874Q30801642-586F4AE7-8E08-4A76-AA05-6D35305256FBQ33161260-63F535C6-2A3C-46A6-8A2D-25D4F3A86BBCQ33575466-7959E4A2-CBD7-49F6-A842-1E31621D8F87Q34029374-B946DE5F-4BDD-4CF0-8DC9-4BF81205E51BQ34604574-6E15F06F-3C6A-43F6-873D-5E16AF569A5EQ34623856-FE6CF727-D7F7-497E-86E5-255AD9A77FF2Q34794295-24AFF2F9-08B2-4BFA-912B-01ABF9BE81C4Q34979344-D3A2887A-BBEB-4184-A814-13687D3363E4Q35040868-856278D7-8EDC-4363-ABAD-FDD95BB8F661Q35095218-FD653B00-D7E8-40A3-BBE9-CC8D756A95D4Q35117827-C8E21074-600D-4656-BF83-8CBFE27DA2EAQ35163697-68A4D77E-C077-49F8-89A4-67A06F2BA22EQ35193179-B611A22C-BEA4-4C6A-835C-CFEB0BD03BB4Q35322603-29D2E1CF-57AE-4953-AB22-8D654FBB4A59Q35322784-68E977A7-33BB-4132-A125-84DF18448BA7Q35946777-A0208C14-D7CC-4D86-A82C-76B40E43B3C0Q36055963-80A963D8-01FF-469F-87B1-11F76DE6B0C7Q36933639-14C77A8B-A355-4390-B215-E39374A40543Q37121967-48FD9512-072C-420F-805C-3E182868EA4EQ37231877-F12CECCC-5991-495F-9BFA-D2961619EB0EQ37285559-3A381EC5-7360-4E38-B5FC-3CDC9785B8F9Q37632774-C3780CA9-4CBA-44EE-B132-F02D3770B081Q37778289-63ED8707-6826-4E86-893B-C5A4D883227EQ37800937-C7945473-81E2-4813-8CA1-0958427D94EAQ37852717-19F43782-89C8-49E7-9FDF-15734DFA18B6Q37885396-A05BDEC0-545A-44E5-800A-E8110A165CBAQ38087506-DCFCBCC3-880C-48B5-8A20-8AE42998316BQ38118172-C9C708FA-860D-4973-9DD4-31F1E6049130Q38202541-5E639048-E5C6-4FEA-A6DC-336AA579C77FQ38240474-D6CC6BFF-BC89-49EE-87B2-A7CCFB001274Q38483005-2C837C00-3FA0-4508-A664-755FB093270BQ38542586-A0D79396-9931-4827-836C-52BA0126FE15Q38574776-1EC7A073-A64D-4D94-A9C2-2D3300A7A174Q38586048-1F55AE63-6A17-420A-9897-5A10AC2F1683
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and tolerability of omalizumab.
@ast
Safety and tolerability of omalizumab.
@en
type
label
Safety and tolerability of omalizumab.
@ast
Safety and tolerability of omalizumab.
@en
prefLabel
Safety and tolerability of omalizumab.
@ast
Safety and tolerability of omalizumab.
@en
P2093
P1476
Safety and tolerability of omalizumab.
@en
P2093
P304
P356
10.1111/J.1365-2222.2009.03214.X
P577
2009-03-17T00:00:00Z